Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

Hungin, 2005, Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact, Aliment Pharmacol Ther, 21, 1365, 10.1111/j.1365-2036.2005.02463.x Longstreth, 2006, Functional bowel disorders, Gastroenterology, 130, 1480, 10.1053/j.gastro.2005.11.061 Drossman, 2009, International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit, J Clin Gastroenterol, 43, 541, 10.1097/MCG.0b013e318189a7f9 Pare, 2006, Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study, Clin Ther, 28, 1726, 10.1016/j.clinthera.2006.10.010 Brandt, 2009, An evidence-based systematic review on the management of irritable bowel syndrome, Am J Gastroenterol, 104, S1, 10.14309/00000434-200901001-00002 Eutamene, 2008, Effect of oral cyclic GMP on two distinct visceral pain models, Neurogastroenterol Motil, 22, 75 Eutamene, 2010, Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain, Neurogastroenterol Motil, 22, 10.1111/j.1365-2982.2009.01385.x Currie, 1992, Guanylin: an endogenous activator of intestinal guanylate cyclase, Proc Natl Acad Sci U S A, 89, 947, 10.1073/pnas.89.3.947 Forte, 2004, Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics, Pharmacol Ther, 104, 137, 10.1016/j.pharmthera.2004.08.007 Bueno, 2004, Antinocicetive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain, Am J Gastroenterol, 99, A283, 10.14309/00000434-200410001-00863 Ustinova, 2008, Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in a animal model of experimental pain, Am J Gastroenterol, 486 Kurtz, 2006, Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacoldynamics in healthy subjects, Gastroenterology, 130, A26 Andresen, 2007, Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome, Gastroenterology, 133, 761, 10.1053/j.gastro.2007.06.067 Thompson, 1999, Functional bowel disorders and functional abdominal pain, Gut, 45, II43 Heaton, 1994, An office guide to whole-gut transit time, J Clin Gastroenterol, 19, 28, 10.1097/00004836-199407000-00008 Francis, 1997, The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 395, 10.1046/j.1365-2036.1997.142318000.x Patrick, 1998, Quality of life in persons with irritable bowel syndrome: development and validation of a new measure, Dig Dis Sci, 43, 400, 10.1023/A:1018831127942 Conover, 1999 Drossman, 2007, Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment, Am J Gastroenterol, 102, 1442, 10.1111/j.1572-0241.2007.01283.x Spiegel, 2008, Predictors of patient-assessed illness severity in irritable bowel syndrome, Am J Gastroenterol, 103, 2536, 10.1111/j.1572-0241.2008.01997.x Camilleri, 2008, A placebo-controlled trial of prucalopride for severe chronic constipation, N Engl J Med, 358, 2344, 10.1056/NEJMoa0800670 Passos, 2009, Adequate relief in a treatment trial with IBS patients: a prospective assessment, Am J Gastroenterol, 104, 912, 10.1038/ajg.2009.13 Whitehead, 2006, Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement, Am J Gastroenterol, 101, 1057, 10.1111/j.1572-0241.2006.00535.x Johnston, 2009, Pilot study on the effect of linaclotide in patients with chronic constipation, Am J Gastroenterol, 104, 125, 10.1038/ajg.2008.59 Bryant, 2010, Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract, Life Sciences, 86, 760, 10.1016/j.lfs.2010.03.015 Busby, 2010, Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit, European Journal of Pharmaology, 10.1016/j.ejphar.2010.09.019 Winawer, 2003, Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence, Gastroenterology, 124, 544, 10.1053/gast.2003.50044